Birgit C. Schultes - Concepedia

Author

Birgit C. Schultes

Momenta Pharmaceuticals (United States)ORCID

Also Known As

B Schultes, B. C. Schultes, B. Schultes, B.C. SCHULTES, B.C. Schultes, BIRGIT C. SCHULTES, BIRGIT SCHULTES, Birgit C Schultes, Birgit C. SCHULTES, Birgit C. Schultes

102

Publications

Citations

H-Index

Concepts

All Affiliations

Momenta Pharmaceuticals (United States)Altarum Institute University of Alberta UPMC Hillman Cancer Center Wellesley College

About

Birgit C. Schultes is an author at Momenta Pharmaceuticals (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	18	1.2K
2	Health Sciences	2	2	24
3	Natural Sciences	2	2	262
4	Allergy	2	2	76
5	Engineering	1	1	13

Birgit C. Schultes

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity Nathaniel Washburn, Inessa Schwab, Daniel Ortiz, Proceedings of the National Academy of Sciences Intravenous ImmunoglobulinImmunologyTherapeuticsImmunotherapyPharmaceutical Chemistry	2015	223
Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer Jonathan S. Berek, Peyton T. Taylor, Alan N. Gordon, Journal of Clinical Oncology	2004	196
M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis He Zhou, Sucharita Roy, Edward Cochran, PLoS ONE ImmunologyTumor ProgressionPathologyImmunoeditingImmunotherapeutics	2011	176
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer Jonathan S. Berek, Peyton T. Taylor, William P. McGuire, Journal of Clinical Oncology	2008	170
Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo A.A. Noujaim, Birgit C. Schultes, Richard P. Baum, Cancer Biotherapy and Radiopharmaceuticals Immunocytochemical TechniqueT Cell ResponsesImmunologyCa125-specific BPathology	2001	110
Anti-idiotype induction therapy: anti-CA125 antibodies (Ab 3 ) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab 1 ) Birgit C. Schultes, Richard P. Baum, A. Niesen, Cancer Immunology Immunotherapy MedicineImmunologyImmune Checkpoint InhibitorAnti-idiotype Induction TherapyAnti-cancer Agent	1998	91
CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients Alan N. Gordon, Birgit C. Schultes, Holly H. Gallion, Gynecologic Oncology Cancer ImmunosurveillanceTumor-specific T-cell ResponsesMedicineImmunologyImmune Checkpoint Inhibitor	2004	89
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer Tom Ehlen, P. Hoskins, David F. Miller, International Journal of Gynecological Cancer	2005	81
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity Johann S. de Bono, Sun Young Rha, Joseph Stephenson, Annals of Oncology Cancer ImmunosurveillanceMedicineImmunologyTumor ImmunityCellular Antitumor Immunity	2004	68
Generation of CD4+ and CD8+ T Lymphocyte Responses by Dendritic Cells Armed with PSA/Anti-PSA (Antigen/Antibody) Complexes Kathleen Alice. Berlyn, Birgit C. Schultes, Béatrice Leveugle, Clinical Immunology Autoimmune DiseaseDendritic Cells ArmedAdaptive Immune SystemImmunologyAntigen Processing	2001	67

Page 1